I need to continue reading the filing for more financial data. Based on what's provided, I'll work with the available information.

Evommune, Inc. (NYSE:EVMN) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 12, 2026, disclosing condensed consolidated financial statements and related disclosures.

Key Highlights

  • Total assets of $278.3 million as of September 30, 2026, compared to $224.9 million as of December 31, 2025, according to the filing.
  • Cash and cash equivalents of $47.6 million as of September 30, 2026, up from $44.1 million at December 31, 2025.
  • Short-term investments of $121.1 million and long-term investments of $93.6 million as of September 30, 2026.
  • 41,349,860 shares of common stock outstanding as of November 10, 2026, at a par value of $0.0001 per share.
  • Classified as a non-accelerated filer, smaller reporting company, and emerging growth company under SEC definitions, as indicated on the filing's cover page.

Evommune Balance Sheet Expansion Through Third Quarter 2026

According to the Form 10-Q filed with the SEC, Evommune, Inc. reported total assets of $278,298 thousand as of September 30, 2026, an increase from $224,946 thousand recorded at December 31, 2025. The company is headquartered at 1891 Page Mill Road, Palo Alto, CA 94304, and its common stock trades on the New York Stock Exchange under the symbol EVMN.

The filing's condensed consolidated balance sheet shows current assets of $174,561 thousand as of September 30, 2026, compared to $153,478 thousand at year-end 2025. Within current assets, cash and cash equivalents stood at $47,570 thousand, short-term investments at $121,068 thousand, and prepaid expenses and other current assets at $5,923 thousand. Long-term investments increased to $93,612 thousand from $67,489 thousand at December 31, 2025. Operating lease right-of-use assets, net, rose to $7,252 thousand from $1,469 thousand over the same period.

The filing contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and the company notes that investors are cautioned not to place undue reliance on them. These statements reflect management's beliefs and assumptions as of the filing date and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially. The filing directs readers to the Risk Factors section of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on March 5, 2026, for a fuller description of applicable risk factors.

What Was Disclosed

Evommune filed its Form 10-Q for the quarter ended September 30, 2026, reporting total assets of $278,298 thousand, cash and cash equivalents of $47,570 thousand, and 41,349,860 shares of common stock outstanding as of November 10, 2026.